Study S000967

A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01517568
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 7
Start: 2006-11
Primary completion: 2006-12
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide [3H]
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2006-002293-22

Registered primary outcomes

Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces []
Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022169	Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Malm-Erjefält M, Drug metabolism and disposition: the biological fate of chemicals	2010	Other trial	PMID 20709939 DOI	registry reference RESULT:20709939